President Joe Biden has recently signed the National Defense Authorization Act (NDAA), which includes provisions supporting clinical trials investigating the therapeutic potential of psychedelic drugs such as psilocybin, MDMA, ibogaine, and 5-MeO-DMT for treating post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) in active-duty members of the U.S. military. The legislation requires the Department of Defense to establish a system enabling service members with PTSD or TBI to participate in these clinical trials. The allocated funds for psychedelic research amount to $10 million and can be utilized in collaboration with academic institutions and eligible federal and state agencies.
This initiative was added to the NDAA by Representative Morgan Luttrell, a Texas Republican and member of both the House Armed Services Committee and the NDAA Conference Committee. The inclusion of these provisions in the NDAA reflects a bipartisan effort to explore alternative treatments for mental health conditions among military personnel.
The bill, known as the Douglas Mike Day Psychedelic Therapy to Save Lives Act, is named after Navy SEAL Douglas “Mike” Day, who faced mental health challenges and later died by suicide. Representative Dan Crenshaw, another Texas Republican, originally sponsored the psychedelics research legislation in 2019. Despite being approved by the House as part of last year’s NDAA, the Senate did not include the psychedelic research provisions in the final version of the defense spending bill.
Clinical research on psychedelics, including substances like psilocybin and MDMA, has demonstrated potential therapeutic benefits for conditions such as depression, PTSD, substance misuse disorders, and anxiety. These studies have garnered bipartisan support, with lawmakers recognizing the need to explore innovative and effective treatments for military service members dealing with mental health challenges. The allocated funds aim to facilitate controlled clinical trials, providing an opportunity to better understand the potential benefits of psychedelics in a therapeutic context for military-related PTSD and TBI.
